ARKGARK Genomic Revolution ETF
Seeks long-term growth of capital.
By ARK ETF Trust · Launched 2014
Annual Cost
0.75%
#3,918 of 5,854 · average
Fund Size
$1.7B
#826 of 5,854 · large
Return (1Y)Goal
+57.4%
Track Record
11 years
#1,218 of 5,854 · established
Performance
Total-return NAV · USDGrowth of $10,000
$14,853+48.5%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Active selection
Sector
Health careFocus
Biotech & Genomics
What it actually holds
By weightConcentration
Top 10 holdings = 58.8% of fundmoderately concentrated
TEMPUS AI INC
9.4%
TWIST BIOSCIENCE CORP
9.0%
CRISPR THERAPEUTICS AG
8.9%
10X GENOMICS INC
5.8%
BEAM THERAPEUTICS INC
5.4%
ABSCI CORP
4.8%
NATERA INC
4.1%
ILLUMINA INC
4.0%
INTELLIA THERAPEUTICS INC
3.8%
PERSONALIS INC
3.6%
Asset allocation
Stocks
99.8%
Cash
0.1%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
43.1%High
Year-on-year price swings
Max drawdown
-83.6%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.16Below average
Sortino (3Y)
0.24Moderate downside risk
Listing
- Exchange
- Cboe BZX
Full fund details
- Objective
- Seeks long-term growth of capital.
- Strategy
- Actively manages a portfolio primarily invested in equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy, and consumer discretionary, that are relevant to the genomics revolution. Investments include micro-, small-, medium-, and large-cap companies in both developed and emerging markets.
- Inception date
- October 31, 2014
- Fund family
- ARK ETF Trust
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at ARKG. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-04